This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Brain Stem Glioma Treatment
Adrenocorticotropic Hormone-Producing Pituitary Tumors Treatment
Standard Treatment Options for Adrenocorticotropic Hormone (ACTH)-Producing Pituitary TumorsStandard treatment options for ACTH-producing pituitary tumors include the following:Surgery (usually a transsphenoidal approach).[1,2,3]Surgery plus radiation therapy.[1,2,4]Radiation therapy.[1,2,4]Steroidogenesis inhibitors, including mitotane, metyrapone, ketoconazole, and aminoglutethimide.[1,2,5]For patients with corticotroph adenomas, transsphenoidal microsurgery is the treatment of choice.[1,2] Remission rates reported in most series are approximately 70% to 90%. In a series of 216 patients, who were operated on using a transsphenoidal approach, 75% experienced long-term remission, 21% experienced persistence of Cushing disease, and 9% had recurrence after the initial correction of the hypercortisolism. The average time interval for reoperation was 3.8 years. Seventy-nine percent of the tumors were microadenomas, and 18% were macroadenomas; 86% of the cases with microadenoma had
About This PDQ Summary
PURPOSE OF THIS SUMMARY This PDQ cancer information summary for health professionals provides comprehensive,peer-reviewed,evidence-based information about the treatment of neuroblastoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. REVIEWERS AND UPDATES ...
General Information About Adult Brain Tumors
An adult brain tumor is a disease in which abnormal cells form in the tissues of the brain. There are many types of brain and spinal cord tumors. The tumors are formed by the abnormal growth of cells and may begin in different parts of the brain or spinal cord. Together,the brain and spinal cord make up the central nervous system (CNS). The tumors may be benign (not cancer) or malignant ...
Treatment of Recurrent Childhood Ependymoma
Recurrence is not uncommon in both benign and malignant childhood brain tumors and may develop many years after initial treatment. For ependymoma,delays beyond 10 to 15 years have been reported.[ 1,2 ] Disease generally recurs at the primary tumor site,even in children with malignant ependymomas.[ 3,4 ] Systemic relapse is extremely rare. At time of relapse,a complete evaluation for ...
Changes to This Summary (01 / 30 / 2013)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Treatment of Recurrent Childhood EpendymomaAdded Bouffet et al. as reference 8.This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Thyrotropin-Producing Tumors Treatment
Standard Treatment Options for Thyrotropin-Producing TumorsStandard treatment options for thyrotropin-producing tumors include the following:Surgery (usually a transsphenoidal approach), with or without adjuvant radiation therapy.[1,2] Somatostatin analogues, such as octreotide.[3,4]Transsphenoidal surgery is the treatment of choice for patients with thyrotropic adenomas. Adjuvant radiation therapy may be employed when surgery is known to be noncurative even if the patient is still euthyroid because relapse is inevitable, and the full effect of radiation therapy requires months or years. Medical therapy may be required for patients who still have hyperthyroid symptoms despite surgery and external radiation. Somatostatin analogues are the drugs of choice for treatment; however, the efficacy of treatment may wane with time.[1,2,3,4]Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with pituitary tumor. The
Get More Information From NCI
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about treatment of Childhood Ependymoma.
Pituitary Carcinomas Treatment
Standard Treatment Options for Pituitary CarcinomasStandard treatment options for pituitary carcinomas include the following:Surgery.Dopamine agonists, such as bromocriptine, pergolide, quinagolide, and cabergoline, for prolactin (PRL)-producing carcinomas.Somatostatin analogues, such as octreotide, for growth hormone (GH)-producing and thyroid-stimulating hormone (TSH)-producing carcinomas.Adjuvant radiation therapy, which does not appear to change the disease's outcome.Chemotherapy, which is of little benefit.Some reports indicate that as many as 88% of pituitary carcinomas are endocrinologically active, and adrenocorticotrophin hormone-secreting tumors are the most common. Treatments for patients with pituitary carcinomas are palliative, with the mean survival time ranging from 2 years to 2.4 years, though several case reports of long-term survivors have been published.[2,3,4,5]Treatment options for patients with pituitary carcinomas include resection and dopamine agonists for
PDQ IS A COMPREHENSIVE CANCER DATABASE AVAILABLE ON NCI'S WEB SITE. PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health,the federal government's focal point for biomedical research. .